Temple scientists target DNA repair to eradicate leukemia stem cells

Despite treatment with imatinib, a successful drug that targets chronic myeloid leukemia , a deadly type of cancer, some patients may continue to be at risk for relapse because a tiny pool of stem cells is resistant to treatment and may even accumulate additional genetic aberrations, eventually leading to disease progression and relapse.

http://www.eurekalert.org/pub_releases/2012-12/tuhs-tst120612.php